Labcorp To Pay Up To $872M For BioReference Health Assets, Including 4Kscore Prostate Test
Labcorp will pay up to $872M for OPKO Health's BioReference Health assets, including the 4Kscore prostate cancer test. The deal was announced on Oct. 15, 2023.
How this was made
The 30-second read
Why it matters
The acquisition expands Labcorp's diagnostic portfolio and may improve its competitive positioning in oncology testing, while OPKO receives a substantial cash payout.
Market read
The announcement is a material M&A event with immediate pricing implications for both LH and OPK.
What to watch
Regulatory approval timeline for the Kscore test and potential synergies with Labcorp's existing platform.
Background
Labcorp (LH) is a leading provider of clinical laboratory services; OPKO (OPK) owns BioReference Health, which operates the FDA-cleared Kscore prostate cancer blood test.
Ticker impact
Labcorp announced a $872M acquisition of OPKO's BioReference Health assets, a new primary disclosure affecting its valuation.
likely downside as the market prices in acquisition costs and integration risk
Large cash outlay and integration uncertainty typically weigh on acquirer stock on announcement.
OPKO agreed to sell BioReference Health assets to Labcorp for up to $872M, a fresh primary disclosure that could boost its share price.
likely upside as investors price in the cash proceeds
Cash proceeds from a sizable asset sale generally lift the seller's stock.
Market effects
Consolidation in the clinical laboratory services sector may spur further M&A activity.
U.S. healthcare services market sees modest reallocation of capital.
Limited to U.S. biotech and diagnostics investors.
Counterpoint
The deal could be accretive for Labcorp if the prostate test adds high-margin revenue, offsetting short-term dilution.
Key entities
- CompanyLabcorp
Acquirer, U.S.-listed ticker LH
- CompanyOPKO Health
Seller, U.S.-listed ticker OPK
